06/16 Taiwan BIO Weekly
2025-06-16 |
| Taiwan BIO Weekly |
| Acer Medical ramps up push into smart healthcare 13 June, 2025 Acer Medical (TW: 6857), a subsidiary of the Acer Group, has partnered with Intel to tap into growing opportunities in AI-powered smart healthcare. Acer Medical announced that its AI-assisted diagnostic software, integrated with Intel's hardware and software technologies, can deliver accurate diagnostic results within seconds. Currently, three of its solutions have been launched in over 13 countries, including Taiwan, Thailand, Malaysia, and Indonesia. More... (in Chinese) |
| GlycoNex Announces Publication of Preclinical Study on GNX1021, a Novel Glycan-Targeted ADC for Gastric Cancer Press release 12 June, 2025 GlycoNex, Inc. (TW: 4168), a clinical-stage biotechnology company specializing in glycan-directed cancer immunotherapies, today announced that its first-in-class antibody-drug conjugate (ADC), GNX1021, has demonstrated superior efficacy in preclinical studies, including potent tumor growth inhibition in gastric cancer animal models. GNX1021 may offer a novel treatment option for gastric cancer patients who are ineligible for HER2 or CLDN18-targeted therapies, and its broad activity suggests therapeutic potential across multiple solid tumor types. More... |
| Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease Press release 12 June, 2025 Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation, and anti-inflammatory effects through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment. More... |
| TFBS Bioscience joins forces with gene therapy pioneer to advance therapy for rare diseases 11 June May, 2025 TFBS Bioscience (TW: 6939) announced that Dr. Wuh-Liang Hwu, Honorary Professor at National Taiwan University College of Medicine and gene therapy pioneer, have been working together to develop a novel gene therapy targeting the rare genetic disorder Sialidosis. The approach uses adeno-associated virus serotype 9 (AAV9) as a vector to deliver the sialidase gene into the human body, aiming to provide an effective treatment option for patients. TFBS Bioscience will serve as the manufacturing partner, offering end-to-end services including process development of the AAV9 viral vector, GMP-grade clinical trial drug manufacturing, and quality and safety testing. These services will support the production of investigational drugs for Phase I/II clinical trials. More... (in Chinese) |
| Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025 Press release 11 June, 2025 Energenesis Biomedical Co., Ltd. (TW: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, MA. The company will be located at Booth #1645 within the Taiwan Pavilion, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson's disease (PD) therapy, ENERGI-F705PD, a first-in-class treatment with disease-modifying potential. More... |
| Oneness Biotech's Bonvadis cream approved by US FDA for all wound indications 11 June, 2025 Oneness Biotech (TW: 4743) announced that it has reached a major milestone in the global commercialization of its innovative medical device with the US FDA approving the marketing authorization for Oneness's Bonvadis (ON101) cream for the treatment of full-thickness chronic wounds. More... (in Chinese) |
| Taiwan Goes All-In for BIO 2025: Showcasing Biotech Innovation, Tech Power, and Global Partnerships 10 June, 2025 Taiwan will participate in the BIO International Convention 2025, held June 16–19 in Boston, with a delegation led by BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office) and organized by the Ministry of Economic Affairs, with support from various government agencies. The Taiwan Pavilion, under the theme "Taiwan, Your Best Partner in Asia," will feature 35 companies, one industry association, and six research institutes (as the following table). Exhibits will focus on AI-driven healthcare, biomanufacturing, and precision medicine, with over 50 technologies addressing health needs across all life stages. Building on momentum from BIO 2024, Taiwan aims to highlight its capabilities in medical informatics, smart healthcare, regenerative medicine, and CDMO services to enhance global biotech collaboration. More... |
| Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025 Press release 10 June, 2025 Caliway Biopharmaceuticals (TW: 6919) announced today its participation in the 2025 BIO International Convention, to be held from June 16 to 19 in Boston, U.S.A. Caliway's Vice President, April Yuan, will deliver an oral presentation on June 17, highlighting the company's latest progress in R&D and pipeline development. The presentation will cover recent updates on CBL-514, first-in-class injectable drug candidate for large-area, site-specific fat reduction, including its development across multiple indications--subcutaneous fat reduction, cellulite, and Dercum's disease. More... |
| Taiwan launches global call on health tech with trade partners 9 June, 2025 Taiwan kicked off its 2025 "Go Healthy with Taiwan" global call for proposals on 3 June which aims to attract global health and sports tech pitches to partner with Taiwanese manufacturers and a chance at a US$30,000 prize. More... |
| tcmc to Showcase Asia's Leading Cell & Gene Therapy CDMO Capabilities at BIO International Convention Press release 9 June, 2025 Taiwan Cell Manufacturing Company (tcmc), (TW: 2330) a leading Contract Development and Manufacturing Organization (CDMO) in cell and gene therapy (CGT), will showcase its advanced manufacturing capabilities and comprehensive services at the 2025 BIO International Convention, June 16-19. Often referred to as the 'TSMC of the CGT industry,' tcmc's presence at this premier global biotechnology event underscores its pivotal role in driving CGT innovation from Asia to the world. More... |
| AmCad BioMed enters Middle East market with trial of handheld ultrasound device 9 June, 2025 AmCad BioMed (TW: 4188) announced that its self-developed handheld ultrasound device, AmCAD-UT LIVE (POCUS -- Point-of-care Ultrasound), which integrates real-time AI analysis and thyroid ultrasound assistance software, has been selected for trial use by the Jordanian government. If testing proves successful, the device is expected to be officially adopted across more than 20 hospitals under the Jordanian royal medical system for clinical examinations and outreach in remote areas. More... (in Chinese) |
| Taiwan Bio Therapeutics' new cell therapy for knee osteoarthritis enters Phase III clinical trial 8 June, 2025 Taiwan Bio Therapeutics (TW: 6892) announced today that its allogeneic cell therapy drug Chondrochymal for knee osteoarthritis has received approval from the Taiwan Food and Drug Administration (TFDA) to begin Phase III clinical trials, with a target completion date in 2028. The Phase III trial will recruit 222 knee osteoarthritis patients at Taichung Veterans General Hospital. It will be a placebo-controlled, parallel-group study using intra-articular injections to evaluate the long-term efficacy and safety of Chondrochymal. More... (in Chinese) |
| Formosa Pharmaceuticals boosted by new eye disease drug 8 June, 2025 Formosa Pharmaceuticals (TW: 6838) has seen a surge in buying interest as its new eye disease treatment drug APP13007 progresses with regulatory filings and marketing authorizations across various countries. Over the past 10 days, the stock has climbed 19.6 percent, including a 5.43 percent gain on the 6th, closing at NT$31.05, a near two-month high, with 4,361 shares traded. Both technical and fundamental indicators are signaling bullish momentum. APP13007, developed with Formosa's proprietary APNT nano-micellar formulation technology, is the first new corticosteroid drug introduced to the US ophthalmology market in 15 years, and is designed to treat inflammation and pain following ocular surgery. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |